These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 1394707)

  • 1. Mechanisms of pharmacokinetic interaction between propranolol and quinidine in rats.
    Yamada K; Yasuhara M; Yatsuzuka A; Okumura K; Sakurai T; Kawai C; Hori R
    Chem Pharm Bull (Tokyo); 1992 Jul; 40(7):1876-9. PubMed ID: 1394707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of pharmacokinetic interaction between ajmaline and quinidine in rats.
    Yamada K; Yatsuzuka A; Yasuhara M; Okumura K; Hori R; Sakurai T; Kawai C
    J Pharmacobiodyn; 1986 Apr; 9(4):347-51. PubMed ID: 3735057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man.
    Yasuhara M; Yatsuzuka A; Yamada K; Okumura K; Hori R; Sakurai T; Kawai C
    J Pharmacobiodyn; 1990 Nov; 13(11):681-7. PubMed ID: 2093126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation.
    Zhou HH; Anthony LB; Roden DM; Wood AJ
    Clin Pharmacol Ther; 1990 Jun; 47(6):686-93. PubMed ID: 2357863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nitric oxide induced sinusoidal relaxation after a propranolol priming dose in the perfused rat liver reduces propranolol availability on subsequent dosing.
    Liu X; Zou Y; Khlentzos AM; Yang Y; Nikolovski J; Weiss M; Roberts MS
    Clin Exp Pharmacol Physiol; 2010 Oct; 37(10):1028-33. PubMed ID: 20659130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Digoxin quinidine interaction: a pharmacokinetic study in the isolated perfused rat liver.
    Ben-Itzhak J; Bassan HM; Shor R; Lanir A
    Life Sci; 1985 Aug; 37(5):411-5. PubMed ID: 4021722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
    Booth CL; Brouwer KR; Brouwer KL
    Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The inhibitory effects of cimetidine on elimination and distribution of propranolol in rats.
    Shibasaki S; Asahina M; Kawamata Y; Kojo M; Nishigaki R; Umemura K
    J Pharmacobiodyn; 1989 Sep; 12(9):549-57. PubMed ID: 2614643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of experimental renal failure on the disposition kinetics of l-propranolol in rats.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1983 Nov; 227(2):295-301. PubMed ID: 6631714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of D-propranolol following oral, intra-arterial and intraportal administration: contrasting effects of oral glucose pretreatment.
    Chow HH; Lalka D
    Biopharm Drug Dispos; 1993 Apr; 14(3):217-31. PubMed ID: 8490110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic interaction between quinidine and digoxin: role of inhibition of sinusoidal Na⁺/K⁺ ATPase digoxin binding.
    Li P; Weiss M; Roberts MS
    Eur J Pharm Sci; 2012 Sep; 47(2):506-11. PubMed ID: 22820029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of some cardiovascular properties of propranolol, MJ 1999 and quinidine in relation to their effects in hypertensive animals.
    Farmer JB; Levy GP
    Br J Pharmacol; 1968 Sep; 34(1):116-26. PubMed ID: 5676002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quinidine pharmacokinetics in patients with cirrhosis or receiving propranolol.
    Kessler KM; Humphries WC; Black M; Spann JF
    Am Heart J; 1978 Nov; 96(5):627-35. PubMed ID: 263396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toxicokinetics of a single intravenous dose of rac-propranolol versus optically pure propranolol in the rat.
    Bode W; Toet AE; Stolker AA; van Ginkel LA; Groen K; Wemer J; de Wildt DJ
    Chirality; 1995; 7(8):626-31. PubMed ID: 8593256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on active transport of (E)-10-hydroxynortriptyline in the kidney and brain of rats: effects of propranolol and quinidine.
    Otani K; Kaneko S; Bertilsson L
    Pharmacol Toxicol; 1991 May; 68(5):380-3. PubMed ID: 1946183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propranolol elimination as described by the venous equilibrium model using flow perturbations in the isolated perfused rat liver.
    Smallwood RH; Mihaly GW; Smallwood RA; Morgan DJ
    J Pharm Sci; 1988 Apr; 77(4):330-3. PubMed ID: 3379592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent presystemic elimination of propranolol due to hepatic first-pass metabolism in rats.
    Iwamoto K; Watanabe J
    J Pharm Pharmacol; 1985 Nov; 37(11):826-8. PubMed ID: 2867168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of phenobarbital and cimetidine on the elimination kinetics and distribution in the heart and liver of propranolol in rats with acute and chronic inflammations].
    Lutsevich AN; Reshet'ko OV; Bogoslovskaia SI
    Eksp Klin Farmakol; 1996; 59(3):47-52. PubMed ID: 8974585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.